These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28622419)

  • 1. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
    Papatheodoridis GV; Idilman R; Dalekos GN; Buti M; Chi H; van Boemmel F; Calleja JL; Sypsa V; Goulis J; Manolakopoulos S; Loglio A; Siakavellas S; Keskın O; Gatselis N; Hansen BE; Lehretz M; de la Revilla J; Savvidou S; Kourikou A; Vlachogiannakos I; Galanis K; Yurdaydin C; Berg T; Colombo M; Esteban R; Janssen HLA; Lampertico P
    Hepatology; 2017 Nov; 66(5):1444-1453. PubMed ID: 28622419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
    Papatheodoridis GV; Dalekos GN; Yurdaydin C; Buti M; Goulis J; Arends P; Sypsa V; Manolakopoulos S; Mangia G; Gatselis N; Keskın O; Savvidou S; Hansen BE; Papaioannou C; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
    J Hepatol; 2015 Feb; 62(2):363-70. PubMed ID: 25195548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
    Choi H; Seo GH
    J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
    Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
    Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
    Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
    Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
    BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
    Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
    Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
    J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
    Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
    Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
    Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.